Diagnostika i farmakoterapiya khronicheskoy obstruktivnoy bolezni legkikh: osnovnye polozheniya
- Authors: Zaytsev A.A1, Bezlepko A.V1, Sinopal'nikov A.I1
-
Affiliations:
- Issue: No 4 (2015)
- Pages: 18-24
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287762
- ID: 287762
Cite item
Open Access
Access granted
Abstract
Chronic obstructive pulmonary disease (COPD) is characterized by persistent obstructive limitation of ventilatory function which is caused by increased chronic inflammatory response to pathogenic particles or gases. The condition is partially reversible, but usually progresses.The paper reviews the basics of COPD patient clinical evaluation, laboratory tests and diagnostic procedures used for examination in this disease. Differential diagnostic criteria between COPD and asthma are presented and signs that may be helpful in differentiating COPD and other respiratory disorders are described. Current classification of COPD (GOLD 2011/2013) is provided. The paper outlines the basic principles of stable COPD pharmacotherapy including anticholinergics, P2-agonists, inhaled corticosteroids, and some other medications (theophylline, antioxidants, phosphodiesterase-4 inhibitors), as well as their combinations.
Full Text
References
- Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www.goldcopd. org/
- Хроническая обструктивная болезнь легких. Федеральная программа (издание второе, переработанное и дополненное) /Под ред. А.Г. Чучалина. М., 2004 г. 61 с.
- Хроническая обструктивная болезнь легких / Под ред. А.Г. Чучалина. М., 2008. 567 с.
- Чучалин А.Г., Айсанов З.Р., Авдеев С.Н. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. М., 2014. Доступно на: http://www.pulmonology.ru/ publications/guide.php ?clea r_cache=Y
- Tashkin D, Fabbri L. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir. Res. 2010;11:149.
- Donohue J., Fogarty C., Lotvall J., et al. Once_ daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotro-pium. Am. J. Respir. Crit. Care Med. 2010; 182:155-62.
- Vogelmeier C., Kardos P., Harari S., et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir. Med. 2008; 102:1511-20.
- Kardos P., Wensker M., Glaad T., Vodelmeier C. Impact of salmaterol / fluticasone propionate versus salmoterol on exacerbations in severe CORD. Am. J. Respir. Crit. Care Med. 2007;175:144-49. терапии второй линии рекомендуется комбинация трех классов препаратов - ИГКС+длительнодействующий р2-агонист+длительнодействующий антихолинергический препарат. К указанному режиму терапии возможно подключение ингибитора фос-фодиэстеразы-4. В качестве дополнительной терапии больных данной группы может быть рекомендовано применение карбоцистеина.
- Celli B., Calverley P., Anderson J., Ferguson G. The TORCH (Towards a Revolution in CORD Health) study: salmaterol / fluticasone propionate improves health status, reduces exacerbations and improves lung function over three years (abstract). Eur. Respir. J. 2006; 28(suppl 50):34.
- Rabe K. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br. J. Pharmacol. 2011;163:53-67.
- Decramer M. Rutten-van Molken M., Dekhuijzen P.N., et al. Effect of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005;365(8470): 1552-60.
Supplementary files
